Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian Cancer

This study is testing whether adding mirabegron (a drug used for overactive bladder that may also affect the immune system) to a combination of pegylated liposomal doxorubicin (a targeted chemotherapy) and adebrelimab (an immunotherapy drug) improves outcomes for women with relapsed ovarian cancer — cancer that came back after initial treatment. **You may be eligible if...** - You have been diagnosed with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer confirmed by tissue test - Your cancer has come back and your last platinum-based chemotherapy ended less than 12 months ago - You received a standard first-line platinum-based treatment following surgery - Your performance status is good (ECOG 0-1) **You may NOT be eligible if...** - You have not received first-line platinum-based chemotherapy - Your cancer is still responding very well to platinum-based drugs (platinum-free interval of 12 months or more from the last platinum therapy) - You have serious health conditions that would prevent you from tolerating the treatment - Your organ function does not meet the required minimums Talk to your doctor to see if this trial is right for you.